Record new awards and a billion dollar buyback plan
- Net new business awards hit an all-time high of $873 million in the third quarter of 2026.
- The board approved a new $1 billion share repurchase program in October to boost shareholder returns.
- Management deferred official 2027 guidance to February to better track award timing and late-year cancellations.
- Trial cancellations were slightly higher but driven by normal drug failures rather than a lack of biotech funding.
- Oncology continues to drive demand as the metabolic trial mix shifts back to historical norms.
Demand stays strong as buybacks return
Medpace continues to show clear demand for its focused clinical trial model. Net new business awards reached an all-time high of $873 million in the third quarter of 2026, up 10.6 percent from the prior year. This record level of new awards is the best early sign of future sales for a contract research organization.
The bull case centers on this sustained growth and a major return of capital to shareholders. Small and mid-sized drug developers still need help running full-service trials from Phase I through Phase IV. Crucially, the board authorized a new $1 billion share repurchase program in October 2026. This addresses a major open question from earlier in the year and provides a significant catalyst for earnings per share.
The bear case focuses on cycle risk, margins, and the timing of new revenue. Management deferred 2027 guidance to February because cancellations and award timing remain volatile. While recent cancellations were tied to drug failures rather than a lack of biotech funding, they still create short-term revenue pressure. Additionally, a large portion of revenue growth comes from lower-margin reimbursed expenses, which could pressure overall margins if that mix shifts.
Paid to run the trial machine
Medpace helps drug, biotech, and medical device companies run clinical trials. It designs development plans, manages projects, handles regulatory work, monitors clinical sites, manages data, watches drug safety, and supports lab, imaging, and heart reading services.
Most contracts are fee-for-service. They are usually priced as fixed-fee work or by units of service. This means Medpace can make good money when it estimates trial costs well and keeps teams busy. It can also get hurt when a fixed-fee contract takes more work than planned.
Two numbers drive the model. Net new business awards show fresh signed work after cancellations. Backlog shows contracted work not yet recognized as revenue. The risk is that backlog is not cash in the bank. Customers can delay, cut, or cancel trials for reasons outside the control of the company.
Where the trial work sits
Full-service clinical development
This is the core product. Medpace supports trials from Phase I through Phase IV, which lets clients use one main partner instead of many vendors.
Oncology trials
Cancer trials remain one of Medpace's key strengths. Oncology represents over half of overall bookings and continues to see strong demand.
Metabolic Disease trials
Metabolic was a major driver of recent growth, but awards have moderated as the mix shifts back to historical averages.
Central Nervous System trials
CNS work covers brain and nerve disorders. It remains a key focus area for clinical research.
Cardiology trials
Heart disease work is a long-running clinical research need. It provides a stable base of trial work.
AVAI trials
AVAI means antiviral and anti-infective work. It is smaller than metabolic and oncology, but still part of the broad trial platform.
One segment, several therapeutic areas
Medpace reports one operating segment. The mix below uses recent revenue trends by therapeutic area, with oncology leading the current bookings growth.
What could break the story
Elevated trial cancellations
High impact · Medium oddsCancellations remain a source of volatility and were toward the higher end of expectations in the third quarter. Even if driven by normal drug failures rather than funding issues, high cancellation rates reduce the revenue backlog.
Biotech funding turns down
High impact · Medium oddsMedpace depends heavily on small and mid-sized biopharma clients. If funding dries up, these clients may delay, shrink, or cancel trials.
Margin mix gets worse
Medium impact · Medium oddsReimbursed out-of-pocket expenses are a large part of growth. These pass-through costs can make revenue look bigger while adding less profit than service revenue. If service margins weaken, the growth headline may hide pressure underneath.
AI and tech gap
Medium impact · Medium oddsThe company added a risk about machine learning and generative AI in 2025. Poor controls could hurt quality, but too little investment could leave Medpace behind rivals using better trial tools.
In one breath
What does Medpace do?
Medpace is a contract research organization. It helps drug, biotech, and medical device companies run clinical trials, from early human studies through post-market work.
How does Medpace make money?
Medpace charges clients for clinical development services. Contracts are often fixed-fee or based on units of service, and revenue is recognized as trial work is performed.
Why do investors watch net new business awards?
Net new business awards show new trial work won after cancellations. For Medpace, they are a key early signal of future revenue because awards can later move into backlog and then sales.
Why was the new buyback plan important?
Medpace paused its share repurchases early in 2026, raising concerns about capital returns. The new $1 billion authorization announced in October signaled extreme confidence and provided support for earnings per share.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- October 25, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Diagnostics & Research companies
Companies near Medpace Holdings, Inc. in Finn's Diagnostics & Research industry ranking.

